$CTEV News

Claritev Q1 2026 Earnings Call Transcript

Canaccord Genuity Initiates Coverage of Claritev (CTEV) with Buy Recommendation

Canaccord Genuity Initiates Coverage On Claritev with Buy Rating, Announces Price Target of $32

Claritev Corp Says Received DOJ Grand Jury Subpoena In August 2024 For Health Insurance Investigation, Denies Being Identified As Target Following Reported Probe Allegations

Claritev Corporation (CTEV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Claritev Corporation (CTEV) Q1 2026 Earnings Call Transcript

Claritev Corporation 2026 Q1 - Results - Earnings Call Presentation

Claritev (NYSE:CTEV) Slides Premarket Despite Q1 Revenue Beat as Net Loss Widens

Claritev Raises FY2026 Sales Guidance from $980.000M-$1.000B to $985.000M-$1.000B vs $989.607M Est

Claritev Q1 EPS $(4.41) Misses $(3.85) Estimate, Sales $244.678M Beat $236.389M Estimate

Barclays Initiates Coverage of Claritev (CTEV) with Overweight Recommendation

Claritev shares are trading higher after Barclays initiated coverage on the stock with Overweight rating and announced a $28 price target.

Claritev shares are trading higher after Barclays initiated coverage on the stock with Overweight rating and announced a $28 price target.

Barclays Initiates Coverage On Claritev with Overweight Rating, Announces Price Target of $28

Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)

Claritev (CTEV) Price Target Decreased by 35.19% to 42.84

Wells Fargo Maintains Equal-Weight on Claritev, Lowers Price Target to $22

How The Claritev (CTEV) Investment Story Is Shifting As Expectations And Valuation Reset

Claritev Corporation (CTEV) Discusses Business Outlook and Addresses Investor Questions Following Recent Quarter Transcript

Alpha Buying: Following the Insiders Into a Volatile Market